Literature DB >> 33401588

Impact of Body Mass Index on the Development of Inflammatory Bowel Disease: A Systematic Review and Dose-Response Analysis of 15.6 Million Participants.

Akshaya Srikanth Bhagavathula1, Cain C T Clark2, Jamal Rahmani3, Vijay Kumar Chattu4,5.   

Abstract

BACKGROUND: A growing trove of literature describes the effect of malnutrition and underweight on the incidence of inflammatory bowel disease (IBD). However, evidence regarding the association between underweight or obesity and IBD is limited. The study aimed to assess the association of body mass index (BMI) with a risk of IBD (Crohn's disease (CD) and ulcerative colitis (U.C.)) incidence.
METHODS: We systematically searched PubMed/Medline, Cochrane, Web of Science, and Scopus for observational studies assessing the association between BMI and IBD that were published up to 30 June 2020. We estimated pooled hazard ratios (HR) with corresponding 95% confidence intervals (CI). Random effect dose-response meta-analysis was performed using the variance weighted least-squares regression (VWLS) models to identify non-linear associations.
RESULTS: A total of ten studies involving 15.6 million individuals and 23,371 cases of IBD were included. Overall, obesity was associated with an increased IBD risk (HR: 1.20, 95% CI: 1.08-1.34, I 2 = 0%). Compared to normal weight, underweight (BMI < 18.5 kg/m2) and obesity (BMI ≥ 30 kg/m2) were associated with a higher risk of CD, and there was no difference in the risk of U.C. among those with BMI < 18.5 kg/m2 and BMI ≥ 30 kg/m2. There was a significant non-linear association between being underweight and obesity and the risk of development of CD (Coef1 = -0.0902, p 1 < 0.001 Coef2 = 0.0713, p 2 < 0.001).
CONCLUSIONS: Obesity increases the risk of IBD development. Underweight and obesity are independently associated with an increased risk of CD, yet there is no evident association between BMI and the risk of U.C. Further studies are needed to clarify the underlying mechanism for these findings, particularly in CD.

Entities:  

Keywords:  Crohn’s disease; body mass index; dose-response analysis; inflammatory bowel disease; meta-analysis; obesity; systematic review

Year:  2021        PMID: 33401588      PMCID: PMC7824000          DOI: 10.3390/healthcare9010035

Source DB:  PubMed          Journal:  Healthcare (Basel)        ISSN: 2227-9032


  32 in total

1.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

2.  Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease.

Authors:  Konstantinos Karmiris; Ioannis E Koutroubakis; Costas Xidakis; Maria Polychronaki; Theodora Voudouri; Elias A Kouroumalis
Journal:  Inflamm Bowel Dis       Date:  2006-02       Impact factor: 5.325

3.  Measures of obesity and risk of Crohn's disease and ulcerative colitis.

Authors:  Hamed Khalili; Ashwin N Ananthakrishnan; Gauree G Konijeti; Leslie M Higuchi; Charles S Fuchs; James M Richter; Andrew T Chan
Journal:  Inflamm Bowel Dis       Date:  2015-02       Impact factor: 5.325

4.  Body mass index and the risk for Crohn's disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study).

Authors:  Simon S M Chan; Robert Luben; Anja Olsen; Anne Tjonneland; Rudolf Kaaks; Birgit Teucher; Stefan Lindgren; Olof Grip; Timothy Key; Francesca L Crowe; Manuela M Bergmann; Heiner Boeing; Göran Hallmans; Pontus Karling; Kim Overvad; Domenico Palli; Giovanna Masala; Hugh Kennedy; Fiona vanSchaik; Bas Bueno-de-Mesquita; Bas Oldenburg; Kay-Tee Khaw; Elio Riboli; Andrew R Hart
Journal:  Am J Gastroenterol       Date:  2013-01-15       Impact factor: 10.864

5.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  BMJ       Date:  2009-07-21

6.  Factors associated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan.

Authors:  Erika Kuwahara; Yoshitaka Murakami; Takahiro Nakamura; Nagamu Inoue; Masakazu Nagahori; Toshiyuki Matsui; Mamoru Watanabe; Yasuo Suzuki; Yuji Nishiwaki
Journal:  J Gastroenterol       Date:  2016-04-13       Impact factor: 7.527

7.  Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide.

Authors:  F Scaldaferri; M Pizzoferrato; L R Lopetuso; T Musca; F Ingravalle; L L Sicignano; M Mentella; G Miggiano; M C Mele; E Gaetani; C Graziani; V Petito; G Cammarota; E Marzetti; A Martone; F Landi; A Gasbarrini
Journal:  Gastroenterol Res Pract       Date:  2017-01-03       Impact factor: 2.260

Review 8.  Relationship(s) between obesity and inflammatory bowel diseases: possible intertwined pathogenic mechanisms.

Authors:  Andrew Szilagyi
Journal:  Clin J Gastroenterol       Date:  2019-08-26

Review 9.  Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases.

Authors:  Jan Bilski; Agnieszka Mazur-Bialy; Dagmara Wojcik; Marcin Surmiak; Marcin Magierowski; Zbigniew Sliwowski; Robert Pajdo; Slawomir Kwiecien; Aleksandra Danielak; Agata Ptak-Belowska; Thomas Brzozowski
Journal:  Biomolecules       Date:  2019-11-26

10.  Physical Fitness in Adolescence and Subsequent Inflammatory Bowel Disease Risk.

Authors:  Carren Melinder; Ayako Hiyoshi; Oula Hussein; Jonas Halfvarson; Anders Ekbom; Scott Montgomery
Journal:  Clin Transl Gastroenterol       Date:  2015-11-05       Impact factor: 4.488

View more
  4 in total

Review 1.  The metabolic nature of inflammatory bowel diseases.

Authors:  Timon E Adolph; Moritz Meyer; Julian Schwärzler; Lisa Mayr; Felix Grabherr; Herbert Tilg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-07-29       Impact factor: 73.082

2.  Polygenic risk score for alcohol drinking behavior improves prediction of inflammatory bowel disease risk.

Authors:  Antonio F Di Narzo; Amy Hart; Roman Kosoy; Lauren Peters; Aleksandar Stojmirovic; Haoxiang Cheng; Zhongyang Zhang; Mingxu Shan; Judy Cho; Andrew Kasarskis; Carmen Argmann; Inga Peter; Eric E Schadt; Ke Hao
Journal:  Hum Mol Genet       Date:  2021-04-30       Impact factor: 6.150

Review 3.  Role of Adipose Tissue in Inflammatory Bowel Disease.

Authors:  Eva Karaskova; Maria Velganova-Veghova; Milos Geryk; Hana Foltenova; Veronika Kucerova; David Karasek
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

Review 4.  Impact of Obesity on the Course of Management of Inflammatory Bowel Disease-A Review.

Authors:  Agata Michalak; Beata Kasztelan-Szczerbińska; Halina Cichoż-Lach
Journal:  Nutrients       Date:  2022-09-25       Impact factor: 6.706

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.